This study is a non-invasive exploratory phase II trial. Among patients who were clinically
diagnosed as non-alcoholic steatohepatitis (NASH) with liver fibrosis accompanied by elevated
triglycerides (TG) and insulin resistance, the efficacy and safety of chiglitazar sodium
tablets 48mg , 64mg or placebo qd for 18 weeks were observed. The result will provide support
for future clinical studies of Chiglitazar Sodium in the treatment of NASH.